WHO ICTRP trial
An open, multi-center phase I/II clinical study to evaluate the safety…
ChiCTR2400085264 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400085264 |
|---|---|
| Public title | An open, multi-center phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of BYS10 tablets in the treatment of advanced solid tumors patients with RET gene fusion or mutation |
| Scientific title | An open, multi-center phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of BYS10 tablets in the treatment of advanced solid tumors patients with RET gene fusion or mutation |
| Primary sponsor | Cancer Hospital, Chinese Academy of Medical Sciences |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 1-2 |
| Countries | China |
| Conditions | advanced solid tumor |
| Interventions | dose esclation( Phase I): Multiple doses (25~600 mg) of BYS10;dose expansion (Phase II):BYS10 (recommended Phase 2 dose) |
| Registration date | Jun 4, 2024 |
| Target size | dose esclation( Phase I):38;dose expansion (Phase II):200 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: